• Publications
  • Influence
Correction of anemia with epoetin alfa in chronic kidney disease.
TLDR
The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g perDeciliter) was associated with increased risk and no incremental improvement in the quality of life and the use of epoetin alfa targeted to achieve a level of 11.4 g perdeciliter was not associated with an increased risk. Expand
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
TLDR
The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event ordeath or a renal event) and was associated with an increased risk of stroke. Expand
Epidemiology and risk factors of chronic kidney disease in India – results from the SEEK (Screening and Early Evaluation of Kidney Disease) study
TLDR
It should be stressed to all primary care physicians taking care of hypertensive and diabetic patients to screen for early kidney damage, as early intervention may retard the progression of kidney disease. Expand
Hypertension in the developing world: challenges and opportunities.
TLDR
The public health response to this challenge should drive greater promotion of awareness efforts, studies of risk factors for hypertension, and understanding of the impact of lifestyle changes. Expand
A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease.
TLDR
The ability of the Modification of Renal Disease (MDRD) equation to predict GFR when compared with multiple other prediction equations in healthy subjects without known kidney disease was analyzed and the MDRD equations are more precise and more accurate for predicting GFR in healthy adults. Expand
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.
TLDR
This study demonstrates that patients achieving their target had better outcomes than those who did not; and among subjects who achieved their randomized target, no increased risk associated with the higher hemoglobin goal was detected. Expand
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated
TLDR
Administration of ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions is superior to no iron therapy in anemic dialysis patients receiving adequate epoetin dosages and have a ferritin 500 to 1200 ng/ml and TSAT <or=25%. Expand
KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
TLDR
While the KDIGO guideline stresses the potential risks of intravenous iron therapy, withholding iron might have its own risks and the recommendation to avoid hemoglobin levels falling below 9 g/dL sets a lower bound of "acceptability" that may increase blood transfusion. Expand
Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
TLDR
The results suggest that the addition of steroid to ACE-inhibitor therapy provided additional benefit compared with an ACE inhibitor alone, and small sample size, a single center, and slight imbalances at baseline suggest further validation is necessary. Expand
Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study.
TLDR
Prevalence of CKD in the young Saudi population is around 5.7%, and screening of high-risk individuals is likely to be the most cost-effective strategy to detect CKD patients. Expand
...
1
2
3
4
5
...